keyword
MENU ▼
Read by QxMD icon Read
search

ius levonorgestrel

keyword
https://www.readbyqxmd.com/read/28730844/correlation-between-uterine-artery-doppler-indices-and-menstrual-irregularities-among-levonorgestrel-releasing-intrauterine-system-and-depot-medroxyprogesterone-acetate-users-a-prospective-observational-study
#1
Mohamed Rezk, Alaa Al-Halaby, Mohamed Emarh, Mohamed Shawky
OBJECTIVE: To ascertain whether menstrual irregularities among users of levonorgestrel releasing intrauterine system (LNG-IUS) and depot medroxyprogesterone acetate (DMPA), were associated with changes in uterine artery Doppler indices or not. METHODS: This three-year prospective observational study included 102 women using LNG-IUS and 104 women using DMPA for contraception. Participants were followed at regular intervals over three years with performance of transvaginal ultrasound to measure uterine artery pulsatility index (PI) and resistance index (RI) before starting the method and at six months, 12 months, two and three years thereafter...
July 21, 2017: European Journal of Contraception & Reproductive Health Care
https://www.readbyqxmd.com/read/28696796/lng-ius-12-a-19-5-levonorgestrel-releasing-intrauterine-system-for-prevention-of-pregnancy-for-up-to-five-years
#2
Anita L Nelson
Globally, intrauterine devices (IUDs) are the second most commonly used form of reversible contraception because of their high efficacy, safety, convenience and cost effectiveness. The levonorgestrel releasing intrauterine system with daily average release of 20 mcg (LNG-IUS 20) is the popular choice because of its favorable bleeding patterns and many noncontraceptive benefits. A three year (LNG-IUS 8) became available three years ago. More recently, the LNG-IUS 12 was added. This new IUD shares a smaller frame, narrow inserter and lower rate of amenorrhea with the LNG-IUS 8, but it offers the five years of contraceptive protection of the LNG-IUS 20...
July 11, 2017: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/28693985/cardiovascular-risk-markers-among-obese-women-using-the-levonorgestrel-releasing-intrauterine-system-a-randomised-controlled-trial
#3
Lucimara Facio Nobre Zueff, Anderson Sanches de Melo, Carolina S Vieira, Wellington P Martins, Rui A Ferriani
According to international guidelines, women with obesity without other comorbidities can safely use any hormonal contraceptive (HC). However, limited information is available about contraceptive safety for women with obesity since obesity is an exclusion criterion of most contraceptive clinical trials. As such little is known about the possible risks of HC exposure for women with obesity without comorbidities. One way to assess possible long-term risks in this population, even prior to the development of any clinical disease, is to measure alterations in subclinical atherosclerosis markers...
July 7, 2017: Obesity Research & Clinical Practice
https://www.readbyqxmd.com/read/28692170/expulsions-and-adverse-events-following-immediate-and-later-insertion-of-a-levonorgestrel-releasing-intrauterine-system-after-medical-termination-of-late-first-and-second-trimester-pregnancy-a-randomised-controlled-trial
#4
Riina Korjamo, Maarit Mentula, Oskari Heikinheimo
OBJECTIVE: To compare expulsions and adverse events (AEs) between immediate and delayed insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS) following medical termination of pregnancy (MTOP). DESIGN: Randomised controlled trial. SETTING: Helsinki University Hospital, Finland, Jan 2013-Dec 2014. POPULATION: 102 (gestational age 64-84 days, late first trimester) and 57 (gestational age 85-140 days, second trimester) women requesting MTOP and LNG-IUS contraception...
July 10, 2017: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28683602/postoperative-levonorgestrel-releasing-intrauterine-system-insertion-after-gonadotropin-releasing-hormone-agonist-treatment-for-preventing-endometriotic-cyst-recurrence-a-prospective-observational-study
#5
Min Kyoung Kim, Seung Joo Chon, Jae Hoon Lee, Bo Hyon Yun, SiHyun Cho, Young Sik Choi, Byung Seok Lee, Seok Kyo Seo
OBJECTIVE: The aim of this study was to evaluate the effectiveness of postoperative levonorgestrel-releasing intrauterine system (LNG-IUS) insertion after gonadotropin-releasing hormone agonist (GnRH-a) treatment for preventing endometriotic cyst recurrence. STUDY DESIGN: The LNG-IUS was applied to 28 women who had undergone surgery for endometriosis followed by 6 cycles of GnRH-a treatment. Clinical characteristics, endometriosis recurrence, and adverse effects were analyzed...
January 1, 2017: Reproductive Sciences
https://www.readbyqxmd.com/read/28675069/clarification-of-the-role-of-the-jaydess-skyla-lng-ius-13-5mg-and-kyleena-lng-ius-19-5mg-as-intrauterine-contraceptive-systems
#6
Norman D Goldstuck
Jaydess/Skyla and Kyleena are 'low dose' levonorgestrel releasing intrauterine systems(LNG-IUS). They differ from Mirena and other similar LNG-IUSs in terms of pharmacological properties and physical dimensions. There are currently no defined guidelines to decide when to use Jaydess or Kyleena or Mirena. Areas covered: MEDLINE, POPLINE, PubMed and clinicaltrials.gov were searched using the terms 'Jaydess', 'Skyla', LNG-IUS 13.5mg and 'Kyleena' LNG-IUS 19.5mg. Only clinical research articles as opposed to generalised reviews and opinion papers on the newer LNG-IUSs were considered for review...
July 4, 2017: Expert Review of Medical Devices
https://www.readbyqxmd.com/read/28650566/immediate-vs-delayed-initiation-of-the-levonorgestrel-releasing-intrauterine-system-following-medical-termination-of-pregnancy-one-year-continuation-rates-a-randomised-controlled-trial
#7
Riina Korjamo, Maarit Mentula, Oskari Heikinheimo
OBJECTIVE: To assess the 1-year continuation rates and new pregnancies following immediate vs. delayed insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) after medical termination of pregnancy (MTOP) of up to 20 weeks of gestation. DESIGN: A randomised controlled trial. SETTING: Helsinki University Hospital, Finland, Jan 2013-Dec 2014. POPULATION: 267 women requesting MTOP and planning LNG-IUS for post-MTOP contraception...
June 26, 2017: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28639461/hormonal-contraception-and-breast-cancer-what-more-do-we-need-to-know
#8
Jo Marsden
Most women use hormonal contraception for more than 30 years and for many, this may involve exposure in their older reproductive years when baseline breast cancer risk rises steeply. Overall, the risk of breast cancer diagnosis with exposure to hormonal contraception is very small and outweighed by its contraceptive benefits but despite this, there are still outstanding questions for all methods used in clinical practice due to paucity of available evidence, lack of which should not be taken to imply safety...
January 1, 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28624570/effects-of-intrauterine-contraception-on-the-vaginal-microbiota
#9
Christine M Bassis, Jenifer E Allsworth, Heather N Wahl, Daniel E Sack, Vincent B Young, Jason D Bell
OBJECTIVES: There have been conflicting reports of altered vaginal microbiota and infection susceptibility associated with contraception use. The objectives of this study were to determine if intrauterine contraception altered the vaginal microbiota and to compare the effects of a copper intrauterine device (Cu-IUD) and a levonorgestrel intrauterine system (LNG-IUS) on the vaginal microbiota. STUDY DESIGN: DNA was isolated from the vaginal swab samples of 76 women using Cu-IUD (n=36) or LNG-IUS (n=40) collected prior to insertion of intrauterine contraception (baseline) and at 6 months...
June 15, 2017: Contraception
https://www.readbyqxmd.com/read/28618723/evaluation-of-quality-of-life-and-cost-effectiveness-of-definitive-surgery-and-the-levonorgestrel-intrauterine-system-as-treatment-options-for-heavy-menstrual-bleeding
#10
Cevdet Adigüzel, Sevtap Seyfettinoğlu, Deniz Aka Satar, Sefa Arlier, Eda Eskimez, Fatma Kaya, Hakan Nazik
BACKGROUND/AIM: This study aimed to compare the levonorgestrel intrauterine system (LNG-IUS) with abdominal hysterectomy (TAH) and total laparoscopic hysterectomy (TLH) as first-line treatments for heavy menstrual bleeding (HMB). MATERIALS AND METHODS: Ninety-eight patients aged 20-55 years who complained of regular heavy menstrual bleeding were enrolled in the study. The TAH group included 29 patients, the LNG-IUS group included 34, and the TLH group included 35...
June 12, 2017: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/28617060/levonorgestrel-releasing-intrauterine-system-lng-ius-12-for-prevention-of-pregnancy-for-up-to-five-years
#11
Anita L Nelson
A new five-year low dose, smaller-framed, levonorgestrel-releasing intrauterine contraceptive system (LNG-IUS 12) has been introduced to complement the currently available systems. Areas Covered: This article will provide an overview of this new intrauterine system - its composition and its mechanisms of action as well as the results of the Phase II and III clinical trials of its efficacy, safety and tolerability. Expert Commentary: This new LNG-IUS 12 provides five-year contraceptive protection a pregnancy rate (less than 1%) in first year of use, which puts it into the top tier with the existing LNG-IUS 20 products; however, the LNG-IUS 12 does not have the high rates of amenorrhea often seen with the higher dose devices...
June 19, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28590560/routine-provision-of-intrauterine-contraception-at-elective-cesarean-section-in-a-national-public-health-service-a-service-evaluation
#12
Rebecca Heller, Anne Johnstone, Sharon T Cameron
INTRODUCTION: We conducted a prospective health service evaluation to assess the feasibility and acceptability of routinely offering insertion of intrauterine contraception (IUC) at cesarean section in a maternity setting in the UK. MATERIAL AND METHODS: One month before scheduled cesarean section, women were sent information about postpartum contraception including the option of insertion of IUC at cesarean. Women choosing IUC (copper intrauterine device or levonorgestrel intrauterine system) were followed up in person at six weeks; telephone contact was made at three, six and 12 months postpartum...
June 7, 2017: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/28586411/incidence-and-treatment-of-heavy-menstrual-bleeding-in-general-practice
#13
Marian J van den Brink, Anne Linde Saaltink, Feikje Groenhof, Boudewijn J Kollen, Marjolein Y Berger, Yvonne Lisman-van Leeuwen, Janny H Dekker
Background.: Heavy menstrual bleeding (HMB) is a common problem in women of reproductive age. In 2008, the Dutch guideline for general practitioners (GPs) was revised to recommend the levonorgestrel intrauterine system (LNG-IUS) as a first-choice treatment for HMB. However, GP prescribing practices have not been studied in depth. Objectives.: To investigate the incidence and initial treatment of HMB in general practice, and to identify if there were changes in prescribing practices after the revision of the national guideline in 2008...
June 6, 2017: Family Practice
https://www.readbyqxmd.com/read/28586290/non-contraceptive-benefits-of-intrauterine-levonorgestrel-administration-why-not
#14
Lorenzo Sabbioni, Felice Petraglia, Stefano Luisi
Levonorgestrel intrauterine systems (LNG-IUS) represent a modern therapy for an array of preexisting gynecological conditions, though they were first marketed in Finland in 1990. However, there are countries in which their use is extremely limited by social and cultural factors. This manuscript describes the possible reasons for this misuse, taking in consideration the clinical noncontraceptive benefits of intrauterine levonorgestrel in routinary practice. Medical diseases in which LNG-IUS represent a treatment include abnormal uterine bleeding, iron-deficiency anemia, endometrial hyperplasia, uterine fibroids, adenomyosis, endometriosis, and coagulopathies...
June 6, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28562472/gonadotropin-releasing-hormone-agonist-combined-with-a-levonorgestrel-releasing-intrauterine-system-or-letrozole-for-fertility-preserving-treatment-of-endometrial-carcinoma-and-complex-atypical-hyperplasia-in-young-women
#15
Huimei Zhou, Dongyan Cao, Jiaxin Yang, Keng Shen, Jinghe Lang
OBJECTIVES: The aim of this study was to evaluate the efficacy and safety with gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine system or an aromatase inhibitor (letrozole) in young women with well-differentiated early endometrial carcinoma (EC) and complex atypical hyperplasia (CAH). METHODS: We performed a retrospective analysis including the clinical characteristics of 29 patients younger than 45 years with early well-differentiated endometrioid adenocarcinoma of the uterus (EC) or CAH who were treated at the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, from January 2012 to April 2016...
July 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28545268/-efficacy-and-impact-on-quality-of-life-of-different-drug-treatments-after-partial-resection-of-rectovaginal-endometriosis
#16
T Li, X X Xu, Y Dai, J J Zhang, J H Lang, J H Leng
Objective: To evaluate different postoperative medications as maintenance treatment for rectovaginal endometriosis (RVE) patients after conservative surgery. Methods: RVE patients who underwent transvaginal partial excision from January 2007 to September 2016 with regular outpatient follow-up were retrospectively screened. Those followed by a levonorgestrel-releasing intrauterine system (LNG-IUS) insertion or oral contraceptive drospirenone/ethinylestradiol (DRSP/EE) 3 mg/30 μg administration were enrolled...
May 25, 2017: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/28537655/comparative-effectiveness-and-impact-on-health-related-quality-of-life-of-hysterectomy-vs-levonorgestrel-intra-uterine-system-for-abnormal-uterine-bleeding
#17
G Cozza, A Pinto, V Giovanale, P Bianchi, A Guarino, R Marziani, A Frega, D Caserta
OBJECTIVE: To compare hysterectomy and levonorgestrel intra-uterine system (LNG-IUS) for the treatment of abnormal uterine bleeding (AUB) and iron deficiency anemia. PATIENTS AND METHODS: Retrospective study evaluating quality of life, sexual function, satisfaction and blood hemoglobin concentration improvement in 60 pre-menopausal women treated with hysterectomy or LNG-IUS. All analysis was performed with statistical software SPSS 21.0 (SPSS Inc., Chicago, IL, USA)...
May 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28536231/pregnant-with-a-perforated-levonorgestrel-intrauterine-system-and-visible-threads-at-the-cervical-os
#18
David L Howard, Lauren M Beasley
We present a case in which a patient presented with a pregnancy of unknown location and normally rising human chorionic gonadotropin (hCG) levels but with a levonorgestrel intrauterine device (LNG-IUD) present. The LNG-IUD had been placed 4.5 years ago. Although unintended, this pregnancy was desired. Strings were clearly visible and initial 2D ultrasound suggested intrauterine location of the LNG-IUD. The LNG-IUD could not be removed however. The patient was managed expectantly with close follow-up, serial beta-hCGs and serial ultrasounds until definitive diagnosis of the location of the pregnancy...
May 22, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28525380/comparison-among-fertility-sparing-therapies-for-well-differentiate-early-stage-endometrial-carcinoma-and-complex-atypical-hyperplasia
#19
REVIEW
Qing Zhang, Gonghua Qi, Margaux J Kanis, Ruifen Dong, Baoxia Cui, Xingsheng Yang, Beihua Kong
OBJECTIVE: To compare fertility-sparing therapies including oral progestogens, hysteroscopic resection (HR), and the levonorgestrel- releasing intrauterine system (LNG-IUS) in achieving disease regression, recurrence and live birth rate in well differentiate early-stage endometrial carcinoma (eEC) and complex atypical hyperplasia(CAH). STUDY DESIGN: This was a meta-analysis of previous studies focus on the fertility-sparing therapy for well differentiate early-stage endometrial carcinoma (eEC) and complex atypical hyperplasia (CAH)...
May 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28485895/with-smart-strategies-immediate-postpartum-larc-is-possible
#20
Ara Aiken
No abstract text is available yet for this article.
May 9, 2017: BJOG: An International Journal of Obstetrics and Gynaecology
keyword
keyword
70416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"